Company intelligence / Profile preview

InterAx Biotech AG

Villigen, Aargau, Switzerlandinteraxbiotech.com ↗

Ownership: Private
Employees: ~14
Development stage: Preclinical

Overview

InterAx’s lead program in immuno-oncology has demonstrated reversal of tumor immune evasion by restoring intra-tumoral cytokine levels and recruiting cancer-killing cells, resulting in significant tumor regression in preclinical models. Their metabolic disease programs are developing oral alternatives to injectable GLP‑1/GIP therapies with promising efficacy and improved tolerability profiles. No clinical data reported yet.

Therapeutic areas: OncologyEndocrinology
Modalities: Small moleculesPeptides
Industry: Biotech

Drug pipeline

2 assets

IAX35-Series

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Boehringer IngelheimLundbeckGPCR TherapeuticsEU Commission grants

Beyond the preview

Go deeper on InterAx Biotech AG.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InterAx Biotech AG.

Explore the full profile